

RNS Number : 7643H

**Galileo Resources PLC
07 December 2020**

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).

7 December 2020

**Galileo Resources Plc
("Galileo" or "the Company")**

Exercise of Warrants

Galileo Resources plc ("Galileo" or the "Company") confirms that it has issued a total of 12,500,000 fully paid ordinary shares in the Company (the "New Ordinary Shares") at a price of 0.6p per share pursuant to the exercise of warrants in terms of the Placing Agreement dated 17 October 2019 (RNS announced 18 October 2019). Application will be made for admission of the New Ordinary Shares to trading on AIM ("Admission"), with Admission expected to occur on around 11 December 2020.

Following the issue of the New Ordinary Shares, which rank pari passu to the existing ordinary shares in the Company, the Company has 830,701,193 ordinary shares in issue, all of which have voting rights. Shareholders in the Company may use this figure as the denominator for the calculation, by which they would determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

You can also follow Galileo on Twitter: @GalileoResource

For further information, please contact: Galileo Resources PLC

Colin Bird, Chairman

Tel +44 (0) 20 7581 4477

Edward Slowey, Executive Director
Beaumont Cornish Limited - Nomad

Tel +353 (1) 601 4466
Tel +44 (0) 20 7628 3396

Roland Cornish/James Biddle

Novum Securities Limited - Joint Broker

+44 (0) 20 7399 9400

Colin Rowbury /Jon Belliss

Shard Capital Partners LLP - Joint Broker

Tel +44 (0) 20 7186 9952

Damon Heath

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END